MarketFriction

Nectar Lifescience Ltd

NSE NECLIFE · BSE 532649 · Pharmaceuticals
₹10.23 -2.57%
NSE close2026-10-01
52 week range9.30 - 22.40
Market cap₹207 Cr.
ASM long-term Price band 5% Delivery 62.5%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales39845244135960051010
Expenses3714103933196006025928
Operating Profit27424840-1-0-0-11-2-57-27
OPM %7%9%11%11%-10%-500%-500%-16%77%-4,437%-6,198%
Other Income1101178-130-62-17635-243
Interest21252420000003060
Depreciation1515151500010000
Profit before tax2211558-130-64-1763-88-24
Tax %38%36%95%40%-2%2%-0%-1%0%-339%-22%-37%
Net Profit121368-130-63-17614-68-15
EPS in Rs0.050.070.030.130.250.35-5.80-2.82-7.850.64-3.50-0.79
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,6741,6351,8742,7792,3631,5411,6651,5201,6821,66402
Expenses1,4361,4111,6382,5142,1431,4321,5071,4671,5301,694888
Operating Profit23922423626422010915953152-30-8-86
OPM %14%14%13%10%9%7%10%3.5%9%-1.8%-2,920%-3,520%
Other Income623664-221143155-279-162
Interest123117115148126112797987753636
Depreciation5762646361605759616200
Profit before tax6467635937-8534-4218-162-323-285
Tax %15%18%17%19%15%-14%26%-43%73%-30%-9%
Net Profit5455524832-7325-245-114-293-245
EPS in Rs2.422.472.332.121.42-3.271.12-1.080.22-5.07-15.08-11.50
Dividend Payout %4%2%2%2%4%0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth%%%-78%
Compounded Profit Growth%%%-9161%
Stock Price CAGR-11%-18%-24%-27%
Return on Equity-3%-8%-12%-31%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital222222222222222222222219
Reserves9369329841,0361,0831,1141,0401,0651,0421,047934563
Borrowings9259628789559037799038607546365820
Other Liabilities62864069671069671842344337148650939
Total Liabilities2,5102,5562,5812,7242,7052,6332,3882,3912,1892,1912,047622
Fixed Assets934906881852825785772723662643633105
CWIP919910210010011599857866570
Investments1111101111113
Other Assets1,4851,5511,5971,7711,7801,7331,5171,5821,4491,4821,357504
Total Assets2,5102,5562,5812,7242,7052,6332,3882,3912,1892,1912,047622
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity144169199652392852195134225169-349
Cash from Investing Activity-60-77-18-29-26-33-291752-17-421,208
Cash from Financing Activity-61-89-204-40-201-25211-119-186-205-128-767
Net Cash Flow233-23-412-04-8-02-193
Free Cash Flow648717432204249-10110183195126-341
CFO/OP56%74%92%33%96%134%23%60%252%148%-574%4,132%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days9910711211973618998678276
Inventory Days253260270226151192185197212215184
Days Payable14615416714280104108112100127117
Cash Conversion Cycle207213215203145150166182179170143
Working Capital Days404145674653673776343
ROCE %11%10%10%9%10%8%3%5%-0%6%-5%0%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters55.80%55.80%55.80%55.80%55.80%44.53%44.53%44.53%44.91%44.91%51.84%51.84%
FIIs16.02%16.12%16.98%16.60%3.24%0.73%1.65%0.82%0.62%0.52%0.60%0.50%
DIIs0.00%0.00%0.00%0.00%0.00%0.00%0.15%0.19%0.08%0.00%0.01%0.01%
Government0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%5.84%4.03%3.75%
Public28.17%28.05%27.20%27.57%40.94%54.72%53.64%54.45%54.37%48.73%43.52%43.90%
No. of Shareholders60,28360,76159,94658,23066,74169,48269,24171,97776,47078,12474,83473,834

Fundamentals

Market Cap₹ 207 Cr.
Current Price₹ 10.7
Book Value₹ 30.0
ROCE0.05 %
ROE-31.3 %
Dividend Yield0.00 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)-78%
Compounded Profit Growth (TTM)-9161%
Consolidated figures.
Valuation
Market capRs 199 Cr
Enterprise valueRs 87 Cr
Price to book0.34x
Earnings yield-123.31%
P/E, 3-year average135.23x
P/B, 3-year average0.49x
P/E, 5-year average78.38x
P/B, 5-year average0.46x
Profitability
Net margin, latest quarter-3500.00%
ROE-38.08%
ROCE-27.10%
ROA-21.95%
ROE, 3-year average-16.28%
ROCE, 3-year average-8.83%
ROA, 3-year average-9.03%
ROE, 5-year average-9.75%
ROCE, 5-year average-3.75%
ROA, 5-year average-5.42%
ROIC (approx.)-47.85%
Tax rate9.44%
Other income / net worth-47.83%
Growth
Sales growth QoQ-65.89%
Sales growth YoY (latest quarter)-91.60%
Per share
EPS (TTM)Rs -12.62
EPS (latest year)Rs -15.08
EPS (latest quarter)Rs -0.79
EPS, 3-year averageRs -6.64
EPS, 5-year averageRs -3.98
Book value per shareRs 29.98
Cash flow per shareRs -17.95
Free cash flow per shareRs -17.55
Efficiency
Inventory turnover0.37x
Inventory days995 days
Creditor days117 days
Cash conversion cycle143 days
Working capital days43 days
Leverage
Cash and bankRs 112 Cr
Net debtRs -112 Cr
Interest coverage-6.88x
Owners' fund to total sources93.68%
Cash flow
Cash from Operating Activity (latest year)Rs -349 Cr
Cash from Investing Activity (latest year)Rs 1,208 Cr
Cash from Financing Activity (latest year)Rs -767 Cr
Net Cash Flow (latest year)Rs 93 Cr
Free cash flow (latest year)Rs -341 Cr
Statement figures
Sales (latest quarter)Rs 0 Cr
Operating profit (latest quarter)Rs -27 Cr
Other income (TTM)Rs -162 Cr
EBITDA (TTM)Rs -248 Cr
PBDT (TTM)Rs -284 Cr
Profit before tax (TTM)Rs -285 Cr
Tax (latest year)Rs -31 Cr
Net profit (TTM)Rs -245 Cr
Net profit (latest year)Rs -293 Cr
Net profit (latest quarter)Rs -15 Cr
Depreciation (TTM)Rs 0 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 36 Cr
Cost of goods sold (latest year)Rs 0 Cr
Total income (latest year)Rs -279 Cr
Share capitalRs 19 Cr
ReservesRs 563 Cr
Shareholders' fundsRs 582 Cr
Total assetsRs 622 Cr
Net blockRs 105 Cr
InvestmentsRs 13 Cr
InventoryRs 0 Cr
Other liabilitiesRs 39 Cr
Shares outstanding (crore)19.43
Ownership
Promoter holding51.84% (+7.31 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/B 0.34 is at the 28th percentile (median 0.41).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodNECLIFENifty 50Difference
1 week-6.0%-2.8% -3.2 pts
1 month-15.7%-6.8% -8.9 pts
3 months-12.9%-7.6% -5.3 pts
6 months+10.0%+0.4% +9.6 pts
1 year-30.5%-9.9% -20.6 pts
2 years-75.4%-13.6% -61.8 pts
3 years-58.1%+14.2% -72.2 pts
5 years-65.5%+27.9% -93.4 pts
1 mutual fund schemes hold about ₹0 Cr. Over three months 0 bought more and 0 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Bandhan BSE Healthcare Index Fund0.01%0

Red flags

F-score 2 of 6
lookRepeated losses Net loss in each of the last two years
lookOn NSE surveillance On NSE surveillance: ASM long-term
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹0 Cr -100.0% vs Jun 2025. Net loss ₹15 Cr.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2025-12-24Buy Back
2024-09-13Annual General Meeting
2023-09-14Annual General Meeting
2022-09-13Annual General Meeting
2021-09-13 Annual General Meeting
2020-09-11 Annual General Meeting/Dividend - Rs 0.05 Per Share
2019-09-19 Annual General Meeting/Dividend - Rs 0.05 Per Share
2018-09-19 Annual General Meeting/Dividend- Re 0.05 Per Share
2017-09-20 Annual General Meeting/Dividend - Re 0.05 Per Share
2016-09-22 Annual General Meeting/Dividend - Re 0.10 Per Share
2015-09-22 Annual General Meeting/ Dividend - Re 0.10/- Per Share
2014-08-21Annual General Meeting / Final Dividend - Re 0.10/- Per Share
2013-09-19Annual General Meeting And Dividend Re.0.10 Per Share
2012-09-20Annual General Meeting And Dividend Re.0.10 Per Share
2011-09-21Annual General Meeting And Dividend Re.0.10 Per Share
2010-09-23Annual General Meeting
2010-01-21Int Div-Re.0.25 Per Sharepurpose Revised
2009-09-03Agm/Div-Re.0.10 Per Share
2008-11-12Fv Split Rs.10/- To Re.1/0.1000
2008-09-18Agm/Dividend - 40%
2007-09-18Agm/Final Dividend-20%
2006-09-08Agm
DateTypeWhat it says
2026-09-19General UpdatesPlease find attached herewith Revised Proceedings of 31st Annual General Meeting
2026-09-18Shareholder meetingVoting results.
2026-09-18Shareholder meetingProceedings of Annual General Meeting held on September 18, 2026
2026-08-22General UpdatesPlease find attached herewith letter sent to the members pursuant to Regulation 36(1)(b)of the SEBI (LODR) Regulations, 2015.
2026-08-20Shareholder meetingNotice of Annual General Meeting to be held on September 18, 2026
2026-08-15General UpdatesChange in corporate office of the Company
2026-08-14Record DateRecord date for the purpose of ascertaining the eligibility of members for remote e-voting and/ or polling/ e-voting at 31st AGM is 11-Sep-2026
2026-08-14Board meeting outcomeWe wish to inform you that the board of directors of Nectar Lifesciences Limited ( Company ) in their meeting held on August 14, 2026, have, inter-ali...
2026-08-14Board meeting outcomeNectar Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-06ResignationResignation of Director/KMP/SMP
2026-08-06ResignationResignation of Mr Surulichamy Senthilkumar as Non- Executive Non- Independent Director of the company w.e.f. August 06, 2026.
2026-08-04General UpdatesSale and Surrender of Leasehold Rights in Land Situated in Jammu
2026-07-23General UpdatesUpdate On Slump Sale
2026-07-13General UpdatesChange in the registered office of the Company
2026-05-30Board meeting outcomeNectar Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-04-28General UpdatesUpdate on Slump Sale
2026-04-28LitigationPendency of Litigation(s)/dispute(s) or the outcome impacting the Company
2026-04-09Disclosure under SEBI TakeovSanjiv Goyal self and Karta of Sanjiv (HUF), Raman Goyal has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities a...
2026-04-08General UpdatesGeneral Updates
2026-03-24LitigationPendency of Litigation(s)/dispute(s) or the outcome impacting the Company
2026-03-13Shareholder meetingWith copy of minutes of Postal Ballot
2026-03-12AgreementsIntimation of inter-corporate loan agreement with Avensis Exports Private Limited, a Wholly Owned Subsidiary of the Nectar Lifesciences Limited
2026-03-07LitigationPendency of Litigation(s)/dispute(s) or the outcome impacting the Company
2026-03-06AcquisitionUpdate on Acquisition
2026-03-03General UpdatesUpdation of disclosures by Nectar Lifesciences Limited as per point no. 1 of its letter no. NLL/CS/2026- 659 dated March 02, 2026.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
EPS in the scrip is zero (4 trailing quarters)Long Term Additional Surveillance Measure (Long Term ASM): stage 1
Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.Updated 2026-10-03